![Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression | Business Wire Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression | Business Wire](https://mms.businesswire.com/media/20221205005815/en/1655671/5/Biogen_Logo_Standard.jpg)
Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression | Business Wire
Zuranolone, a breakthrough postpartum depression treatment, was just approved by the FDA. The fast-acting pill can improve symptoms in 3 days
![Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder](https://www.pharmatechglobal.net/images/news-images/Sage_05122019.jpg)
Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder
Sage Therapeutics Gets FDA Breakthrough Therapy Designation for Major Depressive Disorder Drug - Equities News
![Breakthrough Therapy, PRIME and Sakigake: A Comparison Between Neuroscience and Oncology in Obtaining Preferred Regulatory Status - Elena Tomaselli Muensterman, Yijia Luo, Jonathon M. Parker, 2019 Breakthrough Therapy, PRIME and Sakigake: A Comparison Between Neuroscience and Oncology in Obtaining Preferred Regulatory Status - Elena Tomaselli Muensterman, Yijia Luo, Jonathon M. Parker, 2019](https://journals.sagepub.com/cms/10.1177/2168479019874062/asset/images/large/10.1177_2168479019874062-fig1.jpeg)
Breakthrough Therapy, PRIME and Sakigake: A Comparison Between Neuroscience and Oncology in Obtaining Preferred Regulatory Status - Elena Tomaselli Muensterman, Yijia Luo, Jonathon M. Parker, 2019
![Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder | Business Wire Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder | Business Wire](https://mms.businesswire.com/media/20191205005375/en/760722/4/web-ready.jpg)
Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder | Business Wire
![Schematic model for the initial cellular target sites of rapid-acting... | Download Scientific Diagram Schematic model for the initial cellular target sites of rapid-acting... | Download Scientific Diagram](https://www.researchgate.net/publication/325356817/figure/fig1/AS:629992140582912@1527213239449/Schematic-model-for-the-initial-cellular-target-sites-of-rapid-acting-antidepressants-and.png)
Schematic model for the initial cellular target sites of rapid-acting... | Download Scientific Diagram
![Zuranolone: Treatment Of Major Depression (MDD) And Postpartum Depression (PDD)! - Industry news - News - Hefei Home Sunshine Pharmaceutical Technology Co., Ltd Zuranolone: Treatment Of Major Depression (MDD) And Postpartum Depression (PDD)! - Industry news - News - Hefei Home Sunshine Pharmaceutical Technology Co., Ltd](https://www.hsppharma.com/Content/uploads/2021524038/2021111114590156bc59913d334c478993f68b35b23aae.png)